( BOSTON--(BUSINESS WIRE)--Apr 26 2007 -...)Ties Between Physicians and Drug Companies Still Too Strong: the,Prescription Project Offers Solutions to Prevent Conflicts of,Interest,Health

BOSTON--(BUSINESS WIRE)--Apr 26, 2007 - A new study published today in the New England Journal of Medicine ("A National Survey of Physician-Industry Relationships") on the extent of doctor and pharmaceutical company relationships, highlights the need for profession-wide and public policy reforms promoted by The Prescription Project. The article concludes that the existing, voluntary PhRMA (Pharmaceutical Research and Manufacturers of America) Code isn't working.

The Prescription Project offers solutions to this continuing crisis by outlining specific suggestions for academic medical centers, physician leadership and policy makers to end industry influence on medicine:

"The fact that 94% of physicians have relationships with pharmaceutical companies is a clear barrier to a trusting and effective doctor patient relationship. Academic medical centers and professional medical societies must take the lead in protecting public trust in the medical profession by adopting reforms," said David J. Rothman, PhD, Associate Director of The Prescription Project and president of Institute on Medicine as a Profession, which funded the NEJM study.

"Though the financial ties are extensive, the change we are advocating for can be made and must be made. One can look to the example of several leading academic medical centers to see that this approach can work. We now need a profession-wide adoption of those policies at all hospitals, physician practices and professional medical societies," Rothman continued.

"Legislators across the country are concerned about the influence of the pharmaceutical industry on doctors, and how it affects patient care and costs," said Rob Restuccia, Director of The Prescription Project. "Proposals to stem the tide of industry gifts and end data-mining are moving to the floors of state houses nationwide."

-- Today, New York legislators joined with national consumer and senior
'"/>

Page: 1 2
Related medicine technology :

1. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
2. Topline Results of Phase III Study in Acute Ischemic Stroke (Dias-2) Do Not Demonstrate Difference Between Desmoteplase and Placebo
3. Top Line Results of Phase III Study in Acute Ischemic Stroke (DIAS-2) Do Not Demonstrate Difference Between Desmoteplase and Placebo
4. New Data from the US and Japan Support: No Established Causal Link Between Neuropsychiatric Symptoms and Treatment with Tamiflu US Databases Indicate Psychiatric Symptoms Lower in Influenza Patients Taking Tamiflu Versus Those Not Taking Tamiflu
5. Hypertension Education Foundation Survey Results Announced At American Society For Hypertension Annual Meeting Suggests Improved Control Of High Blood Pressure, But Misconceptions Still Exist
6. New Positive Pre-clinical Data for Active Biotechs RA Project I-3D
7. MUSC Research Offers Hope for Those Resistant to Depression Treatment
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Antibiotics Dont Prevent Future Urinary Tract Infections, May Cause Resistance in Future Infections
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery